Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter, Double-blind, Randomized, Parallel-group, Monotherapy, Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) Versus Avonex® (Interferon β 1a) in Patients With Relapsing-Remitting Multiple Sclerosis
Brief Summary: The primary study objective is to test the superiority of Daclizumab High Yield Process (DAC HYP) compared to interferon β 1a (IFN β-1a) in preventing multiple sclerosis (MS) relapse in participants with relapsing remitting multiple sclerosis.

The secondary study objectives are to test the superiority of DAC HYP compared to IFN β-1a in slowing functional decline and disability progression and maintaining quality of life in this participant population.


Options:
A: Arm Label: Ozanimod 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ozanimod | Arm Label: Ozanimod 1 mg; Type: EXPERIMENTAL; Interventions: Drug: Ozanimod | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Ozanimod, Drug: Placebo | Intervention Type: DRUG; Name: Ozanimod; Assigned to Arm(s): Ozanimod 0.5 mg, Ozanimod 1 mg, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Cladribine Low/Placebo (LLPP); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cladribine High Dose/Placebo (HLPP); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cladribine Low/Low Dose (LLLL); Type: EXPERIMENTAL; Interventions: Drug: Cladribine | Arm Label: Cladribine High/Low Dose (HLLL); Type: EXPERIMENTAL; Interventions: Drug: Cladribine | Arm Label: Placebo/Cladribine Low Dose (PPLL); Type: EXPERIMENTAL; Interventions: Drug: Cladribine | Arm Label: Placebo/No Treatment; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Cladribine 3.5 mg/kg/No Treatment; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Cladribine 5.25 mg/kg/No Treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Cladribine; Assigned to Arm(s): Cladribine Low/Low Dose (LLLL) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cladribine Low/Placebo (LLPP) | Intervention Type: DRUG; Name: Cladribine; Assigned to Arm(s): Cladribine High/Low Dose (HLLL) | Intervention Type: DRUG; Name: Cladribine; Assigned to Arm(s): Placebo/Cladribine Low Dose (PPLL) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Cladribine High Dose/Placebo (HLPP)
C: Arm Label: Daclizumab High Yield Process 150 mg SC; Type: EXPERIMENTAL; Interventions: Biological: BIIB019 (Daclizumab High Yield Process), Drug: Interferon beta-1a Placebo | Arm Label: IFN β-1a 30 µg IM; Type: ACTIVE_COMPARATOR; Interventions: Biological: Interferon beta-1a, Drug: Daclizumab High Yield Process Placebo | Intervention Type: BIOLOGICAL; Name: BIIB019 (Daclizumab High Yield Process); Assigned to Arm(s): Daclizumab High Yield Process 150 mg SC | Intervention Type: DRUG; Name: Interferon beta-1a Placebo; Assigned to Arm(s): Daclizumab High Yield Process 150 mg SC | Intervention Type: BIOLOGICAL; Name: Interferon beta-1a; Assigned to Arm(s): IFN β-1a 30 µg IM | Intervention Type: DRUG; Name: Daclizumab High Yield Process Placebo; Assigned to Arm(s): IFN β-1a 30 µg IM
D: Arm Label: Threshold estimates; Type: EXPERIMENTAL; Interventions: Other: descriptive case-scenarios | Arm Label: Alternative threshold estimates; Type: ACTIVE_COMPARATOR; Interventions: Other: descriptive case-scenarios | Intervention Type: OTHER; Name: descriptive case-scenarios; Assigned to Arm(s): Alternative threshold estimates, Threshold estimates

Answer: C